Evidence map›Paper›PMID 32805185›Full record

Trial reportJournal of the American Heart Association2020

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.

Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Nanba, Yoichi Nakamura, Satoshi Akagi and 9 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 8 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 8 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 2 countries.

Kentaro EjiriDepartment of Cardiovascular Medicine Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Okayama Japan.
Toru MiyoshiDepartment of Internal Medicine Tamano City Hospital Okayama Japan.
Hajime KiharaDepartment of Internal Medicine Kihara Cardiovascular Clinic Asahikawa Japan.
Yoshiki HataDepartment of Cardiology Minamino Cardiovascular Hospital Hachioji Japan.
Toshihiko NaganoDepartment of Internal Medicine Iwasa Hospital Gifu Japan.
Atsushi TakaishiDepartment of Cardiology Mitoyo General Hospital Kanonji Japan.
Hironobu TodaDepartment of Cardiovascular Medicine Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Okayama Japan.
Seiji NanbaDepartment of Cardiology Okayama Rosai Hospital Okayama Japan.
Yoichi NakamuraDepartment of Cardiovascular Medicine Specified Clinic of Soyokaze Cardiovascular Medicine and Diabetes Care Matsuyama Japan.
Satoshi AkagiDepartment of Cardiovascular Medicine Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Okayama Japan.
Satoru SakuragiDepartment of Cardiovascular Medicine Iwakuni Clinical Center Iwakuni Japan.
Taro MinagawaDepartment of Internal Medicine Minagawa Cardiovascular Clinic Gifu Japan.
Yusuke KawaiDepartment of Cardiovascular Medicine Okayama City Hospital Okayama Japan.
Nobuhiro NishiiDepartment of Cardiovascular Medicine Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Okayama Japan.
Soichiro FukeDepartment of Cardiovascular Medicine Japanese Red Cross Okayama Hospital Okayama Japan.
Masaki YoshikawaDepartment of Cardiology Fukuyama City Hospital Fukuyama Japan.
Kazufumi NakamuraDepartment of Cardiovascular Medicine Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Okayama Japan.
Hiroshi ItoDepartment of Cardiovascular Medicine Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences Okayama Japan.
MUSCAT‐HF Study Investigators †
Okayama University · JPIwakuni Medical Center · JPAsahikawa City Hospital · JPDiabetes Australia · AUFukuyama City Hospital · JPGifu Heart Center · JPMito Saiseikai General Hospital · JPMiwa Hospital · JPOkayama Prefecture · JPOkayama Red Cross General Hospital · JPOkayama Rosai Hospital · JPSapporo Minami Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Effects of sodium-glucose cotransporter 2 inhibitors on reducing hospitalization for heart failure have been reported in randomized controlled trials, but their effects on patients with heart failure with preserved ejection fraction (HFpEF) are unknown. This study aimed to evaluate the drug efficacy of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus and HFpEF. Methods and Results We performed a multicenter, open-label, randomized, controlled trial for comparing luseogliflozin 2.5 mg once daily with voglibose 0.2 mg 3 times daily in patients with type 2 diabetes mellitus suffering from HFpEF (left ventricular ejection fraction >45% and BNP [B-type natriuretic peptide] concentrations ≥35 pg/mL) in a 1:1 randomization fashion. The primary outcome was the difference from baseline in BNP levels after 12 weeks of treatment between the 2 drugs. A total of 173 patients with diabetes mellitus and HFpEF were included. Of these, 83 patients were assigned to receive luseogliflozin and 82 to receive voglibose. There was no significant difference in the reduction in BNP concentrations after 12 weeks from baseline between the 2 groups. The ratio of the mean BNP value at week 12 to the baseline value was 0.79 in the luseogliflozin group and 0.87 in the voglibose group (percent change, -9.0% versus -1.9%; ratio of change with luseogliflozin versus voglibose, 0.93; 95% CI, 0.78-1.10;

Indexed as

AgedBiomarkersDiabetes Mellitus, Type 2Drug Administration ScheduleFemaleHeart FailureHumansHypoglycemic AgentsInositolMaleMiddle AgedNatriuretic Peptide, BrainProspective StudiesSodium-Glucose Transporter 2 InhibitorsSorbitolStroke Volume1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolBiomarkersHypoglycemic AgentsInositolNatriuretic Peptide, BrainSodium-Glucose Transporter 2 InhibitorsSorbitolvogliboseB‐type natriuretic peptidediabetes mellitusheart failuresodium‐glucose cotransporter 2 inhibitor

Identifiers

PMID32805185
PMCPMC7660815
OpenAlexW3046604383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.